Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

F Labrie

Showing results (631-640 of 723) with videos related to

Pageof 73
Sort By:
Molecular Pharmacology|February 17, 2001
Glucuronidation of the nonsteroidal antiestrogen EM-652 (SCH 57068), by human and monkey steroid conjugating UDP-glucuronosyltransferase enzymesO Barbier, C Albert, I Martineau, et al.
The Prostate|April 1, 1996
Androgen receptor modulation in benign human prostatic tissue and prostatic adenocarcinoma during neoadjuvant endocrine combination therapyT H Van der Kwast, B Têtu, Y Fradet, et al.
Endocrinology|September 1, 1992
Structure of human type II 5 alpha-reductase geneF Labrie, Y Sugimoto, V Luu-The, et al.
Life Sciences|May 15, 1978
Content of beta-LPH and its fragments (including endorphins) in anterior and intermediate lobes of the bovine pituitary glandJ C Lissitsky, O Morin, A Dupont, et al.
Neuropharmacology|April 1, 1980
Activity of two new potent dopaminergic agonists at the striatal and anterior pituitary levelsC Euvrard, L Ferland, T Di Paolo, et al.
The Journal of Clinical Endocrinology and Metabolism|February 1, 1988
Changes in plasma lipoproteins during various androgen suppression therapies in men with prostatic carcinoma: effects of orchiectomy, estrogen, and combination treatment with luteinizing hormone-releasing hormone agonist and flutamideS Moorjani, A Dupont, F Labrie, et al.
Progress in Clinical and Biological Research|January 1, 1988
Combination therapy with flutamide and castration (orchiectomy or LHRH agonist): the minimal endocrine therapy in both untreated and previously treated patients with advanced prostate cancerF Labrie, A Dupont, M Giguère, et al.
Journal of Molecular Endocrinology|July 29, 2000
Intracrinology: role of the family of 17 beta-hydroxysteroid dehydrogenases in human physiology and diseaseF Labrie, V Luu-The, S X Lin, et al.
Acta Crystallographica. Section D, Biological Crystallography|March 27, 2001
Crystallization and preliminary X-ray crystallographic analysis of the human type 3 3 alpha-hydroxysteroid dehydrogenase at 1.8 A resolutionD W Zhu, L Cantin, V Nahoum, et al.
The Prostate|October 1, 1995
Molecular mass and carbohydrate structure of prostate specific antigen: studies for establishment of an international PSA standardA Bélanger, H van Halbeek, H C Graves, et al.
Pageof 73

Showing results (631-640 of 723) with videos related to

Sort By:
Pageof 73
Molecular Pharmacology|February 17, 2001
Glucuronidation of the nonsteroidal antiestrogen EM-652 (SCH 57068), by human and monkey steroid conjugating UDP-glucuronosyltransferase enzymesO Barbier, C Albert, I Martineau, et al.
The Prostate|April 1, 1996
Androgen receptor modulation in benign human prostatic tissue and prostatic adenocarcinoma during neoadjuvant endocrine combination therapyT H Van der Kwast, B Têtu, Y Fradet, et al.
Endocrinology|September 1, 1992
Structure of human type II 5 alpha-reductase geneF Labrie, Y Sugimoto, V Luu-The, et al.
Life Sciences|May 15, 1978
Content of beta-LPH and its fragments (including endorphins) in anterior and intermediate lobes of the bovine pituitary glandJ C Lissitsky, O Morin, A Dupont, et al.
Neuropharmacology|April 1, 1980
Activity of two new potent dopaminergic agonists at the striatal and anterior pituitary levelsC Euvrard, L Ferland, T Di Paolo, et al.
The Journal of Clinical Endocrinology and Metabolism|February 1, 1988
Changes in plasma lipoproteins during various androgen suppression therapies in men with prostatic carcinoma: effects of orchiectomy, estrogen, and combination treatment with luteinizing hormone-releasing hormone agonist and flutamideS Moorjani, A Dupont, F Labrie, et al.
Progress in Clinical and Biological Research|January 1, 1988
Combination therapy with flutamide and castration (orchiectomy or LHRH agonist): the minimal endocrine therapy in both untreated and previously treated patients with advanced prostate cancerF Labrie, A Dupont, M Giguère, et al.
Journal of Molecular Endocrinology|July 29, 2000
Intracrinology: role of the family of 17 beta-hydroxysteroid dehydrogenases in human physiology and diseaseF Labrie, V Luu-The, S X Lin, et al.
Acta Crystallographica. Section D, Biological Crystallography|March 27, 2001
Crystallization and preliminary X-ray crystallographic analysis of the human type 3 3 alpha-hydroxysteroid dehydrogenase at 1.8 A resolutionD W Zhu, L Cantin, V Nahoum, et al.
The Prostate|October 1, 1995
Molecular mass and carbohydrate structure of prostate specific antigen: studies for establishment of an international PSA standardA Bélanger, H van Halbeek, H C Graves, et al.
Pageof 73